Merck Ranked No. 1 in the Pharmaceutical Industry Among Barron’s 100 Most Sustainable U.S. Companies 2023
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the third consecutive year, ranking No. 1 in the pharmaceutical industry and advancing 38 spots…
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients…
Merck Announces First-Quarter 2023 Financial Results
RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2023. “Inspired by our commitment to bring bold science forward to address critical unmet patient needs, we…
Regional Cancer Care Associates Joins The US Oncology Network
The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced that Regional Cancer Care Associates (RCCA) entered into a strategic relationship with The Network effective April 1,…
Biologics by McKesson Named the Exclusive Pharmacy for FDA- Approved SKYCLARYS (omaveloxolone) for the Treatment of Friedreich’s Ataxia
Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Reata Pharmaceuticals as the sole specialty pharmacy provider for SKYCLARYSTM (omaveloxolone), the first and only treatment for Friedreich’s ataxia (FA). SKYCLARYS was approved by the…
McKesson ideaShare Invites Independent Community Pharmacy Teams to Annual Industry Education and Networking Event
McKesson ideaShare in Las Vegas from June 22–25, 2023. McKesson ideaShare is the nation’s premier community pharmacy annual education and networking event, hosted by McKesson, Health Mart, and Health Mart Atlas. The event returns with double the clinical and business educational opportunities, new pharmacy…
Stryker reports first quarter 2023 operating results
Kalamazoo, Michigan, May 01, 2023 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) reported operating results for the first quarter of 2023: First Quarter Results First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions /…
Pfizer Reports First-Quarter 2023 Results
First-Quarter 2023 Revenues of $18.3 Billion – Expected Decline in Comirnaty(1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues – First-Quarter 2023 Revenues from Comirnaty(1) and Paxlovid of $7.1 Billion – Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew…
XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today that XTANDI® (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide (Hazard Ratio [HR]:…
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in…
Pfizer Announces 2023 Shareholder Meeting Preliminary Results
Pfizer Inc. (NYSE: PFE) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual Meeting indicate that the Company’s 12 director nominees were re-elected to one-year terms and that shareholders ratified the selection of…
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2023 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 27, 2023. Pfizer has designed the virtual Annual Meeting…